Cellular and molecular characterization of the scurfy mouse mutant.

Mice hemizygous (Xsf/Y) for the X-linked mutation scurfy (sf) develop a severe and rapidly fatal lymphoproliferative disease mediated by CD4+CD8- T lymphocytes. We have undertaken phenotypic and functional studies to more accurately identify the immunologic pathway(s) affected by this important mutation. Flow cytometric analyses of lymphoid cell populations reveal that scurfy syndrome is characterized by changes in several phenotypic parameters, including an increase in Mac-1+ cells and a decrease in B220+ cells, changes that may result from the production of extremely high levels of the cytokine granulocyte-macrophage CSF by scurfy T cells. Scurfy T cells also exhibit strong up-regulation of cell surface Ags indicative of in vivo activation, including CD69, CD25, CD80, and CD86. Both scurfy and normal T cells are responsive to two distinct signals provided by the TCR and by ligation of CD28; scurfy cells, however, are hyperresponsive to TCR ligation and exhibit a decreased requirement for costimulation through CD28 relative to normal controls. This hypersensitivity may result, in part, from increased costimulation through B7-1 and B7-2, whose expression is up-regulated on scurfy T cells. Although the specific defect leading to this hyperactivation has not been identified, we also demonstrate that scurfy T cells are less sensitive than normal controls to inhibitors of tyrosine kinases such as genistein and herbimycin A, and the immunosuppressant cyclosporin A. One interpretation of our data would suggest that the scurfy mutation results in a defect, which interferes with the normal down-regulation of T cell activation.

[1]  T. Sullivan,et al.  Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells. , 1997, Immunity.

[2]  J. Allison,et al.  The emerging role of CTLA-4 as an immune attenuator. , 1997, Immunity.

[3]  J. Allison,et al.  Co-stimulation in T cell responses. , 1997, Current opinion in immunology.

[4]  A. Weiss,et al.  T cell antigen receptor signal transduction. , 1997, Current opinion in cell biology.

[5]  J. Allison,et al.  T cell-mediated elimination of B7.2 transgenic B cells. , 1997, Immunity.

[6]  G. Freeman,et al.  B7.2 expressed by T cells does not induce CD28-mediated costimulatory activity but retains CTLA4 binding: implications for induction of antitumor immunity to T cell tumors. , 1997, Journal of immunology.

[7]  J. Wang,et al.  IL-2 and IL-4 mediate through two distinct kinase pathways for the activation of alphaCD3-induced activated killer cells. , 1996, Cellular immunology.

[8]  L Timmermann,et al.  The mechanism of action of cyclosporin A and FK506. , 1996, Clinical immunology and immunopathology.

[9]  M. Lovett,et al.  Identification of the homologous beige and Chediak–Higashi syndrome genes , 1996, Nature.

[10]  J. Bluestone,et al.  CD28/B7 system of T cell costimulation. , 1996, Annual review of immunology.

[11]  V. Godfrey,et al.  Disease in the scurfy (sf) mouse is associated with overexpression of cytokine genes , 1996, European journal of immunology.

[12]  D. Hafler,et al.  Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions , 1995, The Journal of experimental medicine.

[13]  J. Bluestone,et al.  Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. , 1995, Immunity.

[14]  U. Francke,et al.  The mouse homolog of the Wiskott-Aldrich syndrome protein (WASP) gene is highly conserved and maps near the scurfy (sf) mutation on the X chromosome. , 1995, Genomics.

[15]  J. Bluestone,et al.  Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse , 1995, The Journal of experimental medicine.

[16]  H. Weiner,et al.  Reciprocal expression of co‐stimulatory molecules, B7‐1 and B7‐2, on murine T cells following activation , 1995, European journal of immunology.

[17]  K. Siminovitch,et al.  Identification of PTP1C mutation as the genetic defect in motheaten and viable motheaten mice: a step toward defining the roles of protein tyrosine phosphatases in the regulation of hemopoietic cell differentiation and function. , 1994, Clinical immunology and immunopathology.

[18]  V. Godfrey,et al.  CD4+CD8- T cells are the effector cells in disease pathogenesis in the scurfy (sf) mouse. , 1994, Journal of immunology.

[19]  P. Linsley,et al.  Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function , 1994, The Journal of experimental medicine.

[20]  P. Linsley,et al.  CTLA-4 can function as a negative regulator of T cell activation. , 1994, Immunity.

[21]  V. Godfrey,et al.  Transplantation of T cell-mediated, lymphoreticular disease from the scurfy (sf) mouse. , 1994, The American journal of pathology.

[22]  G. Freeman,et al.  A negative regulatory function of B7 revealed in B7-1 transgenic mice. , 1994, Immunity.

[23]  D J Rawlings,et al.  Mutation of unique region of Bruton's tyrosine kinase in immunodeficient XID mice. , 1993, Science.

[24]  W. Paul,et al.  Colocalization of X-linked agammaglobulinemia and X-linked immunodeficiency genes. , 1993, Science.

[25]  C. June,et al.  The protein tyrosine kinase inhibitor herbimycin A, but not genistein, specifically inhibits signal transduction by the T cell antigen receptor. , 1992, International immunology.

[26]  P. Linsley,et al.  CTLA-4 is a second receptor for the B cell activation antigen B7 , 1991, The Journal of experimental medicine.

[27]  V. Godfrey,et al.  Fatal lymphoreticular disease in the scurfy (sf) mouse requires T cells that mature in a sf thymic environment: potential model for thymic education. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[28]  K. Dorshkind In vivo administration of recombinant granulocyte-macrophage colony-stimulating factor results in a reversible inhibition of primary B lymphopoiesis. , 1991, Journal of immunology.

[29]  V. Godfrey,et al.  X-linked lymphoreticular disease in the scurfy (sf) mutant mouse. , 1991, The American journal of pathology.

[30]  J. Trevillyan,et al.  Differential inhibition of T cell receptor signal transduction and early activation events by a selective inhibitor of protein-tyrosine kinase. , 1990, Journal of immunology.

[31]  M. Lyon,et al.  The scurfy mouse mutant has previously unrecognized hematological abnormalities and resembles Wiskott-Aldrich syndrome. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[32]  R. Gibbs,et al.  The molecular basis of the sparse fur mouse mutation. , 1987, Science.

[33]  N. Tanaka,et al.  The interleukin-2 receptor gamma chain: its role in the multiple cytokine receptor complexes and T cell development in XSCID. , 1996, Annual review of immunology.

[34]  S. Schreiber,et al.  The mechanism of action of cyclosporin A and FK506. , 1992, Immunology today.